ArticleEndocrine, metabolic & immune disorders drug targets2026
A Histone Deacetylase Activity Model for the Discovery and Validation of Sepsis Biomarkers.
Article in Endocrine, metabolic & immune disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHistone deacetylases (HDACs) play critical roles in immune regulation and inflammatory responses in sepsis. This study identified HDAC-related genes and explored their potential roles in sepsis. MATERIALS AND
methodsHDAC scores were computed by ssGSEA. WGCNA was applied to identify HDAC-related gene modules, followed by functional enrichment analysis. Machine learning methods were employed to screen diagnostic biomarkers. Immune infiltration analysis and molecular docking were performed to validate gene-immune correlations and potential drugs. An in-vitro sepsis model was established by using lipopolysaccharide to induce THP-1-derived macrophages. The gene expression and inflammatory factor levels were assessed using qPCR, Western blot, and ELISA methods. Finally, the effect of TRIM24 knockdown on cell apoptosis and inflammatory responses was analyzed.
resultsTwo HDAC-related genes (TOM1L2, TRIM24) were identified as potential diagnostic biomarkers for sepsis, showing significant correlation with immune cell infiltration. Molecular docking confirmed the binding capacity of Acetaminophen, 8-azaguanine, and Ochratoxin A with the two biomarkers. In-vitro sepsis model showed that TRIM24 knockdown markedly lowered the levels of pro-inflammatory cytokines and apoptosis. DISCUSSION: The two biomarkers, along with the RiskScore model, could potentially contribute to the prognostic assessment of sepsis and the development of personalized treatment. However, further experimental validation is also needed to substantiate our findings and to translate them into practical clinical applications.
conclusionThis study identified TOM1L2 and TRIM24 as key HDAC-related biomarkers for sepsis, providing novel insights for the early diagnosis and targeted treatments of sepsis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.